Duan Qiwen, Liu Junhua, Luo Zhiguo, Hu Chenhao
Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Department of Paediatrics and Epidemiology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Mol Clin Oncol. 2015 May;3(3):550-554. doi: 10.3892/mco.2015.498. Epub 2015 Jan 27.
The aim of the present study was to perform a retrospective analysis of the control rate and toxicity of postoperative brachytherapy and electron beam irradiation for keloids. A retrospective review was performed of 116 keloid patients who underwent postoperative brachytherapy and electron beam irradiation between January 1, 2002 and June 30, 2012. Several different radiotherapy techniques and fractionation schedules were performed in the analysis, including high-dose rate (HDR) irradiation with Ir at 8 Gy/1 fraction (F)+9 Gy/3F or 20 Gy/4F; HDR brachytherapy with Co at 20 Gy/4F or 18 Gy/6F; or external beam electron therapy at 26 Gy/13F or 30 Gy/15F. The endpoints of the study were analysis of the control rate and toxicity. The median observation period was 46.5 months (range, 10.0-120.0 months) for all patients. In total, 18 of the 116 patients relapsed, and 16.7 months (range, 10.0-30.0 months) was the median time to recurrence for these patients. The control rates for the patients who received hypofractionation (>2 Gy per fraction) and conventional fraction (2 Gy per fraction) were 88.5 and 76.3%, respectively (P=0.043). The control rates for the patients whose calculated biological effective doses (BED) were >30 Gy and <30 Gy were 89.7 and 79.3%, respectively (P=0.104). There were no grade 2 or higher adverse effects based on the Common Terminology Criteria for Adverse Events v3.0 in the late phase. No evidence was identified for a link between radiotherapy and the subsequent occurrence of cancer. The results of the present study indicate that hypofractionated radiotherapy played an important role as an adjuvant therapy following surgical excision of keloids. A BED of >30 Gy appears to be sufficient. No definitive evidence was found for an association between radiotherapy and the occurrence of cancer during the follow-up, however, more cases and longer follow-up periods are required.
本研究旨在对瘢痕疙瘩术后近距离放疗和电子束照射的控制率及毒性进行回顾性分析。对2002年1月1日至2012年6月30日期间接受术后近距离放疗和电子束照射的116例瘢痕疙瘩患者进行了回顾性研究。分析中采用了几种不同的放疗技术和分割方案,包括以铱进行高剂量率(HDR)照射,剂量为8 Gy/1次分割(F)+9 Gy/3次分割或20 Gy/4次分割;以钴进行HDR近距离放疗,剂量为20 Gy/4次分割或18 Gy/6次分割;或外照射电子治疗,剂量为26 Gy/13次分割或30 Gy/15次分割。研究的终点是分析控制率和毒性。所有患者的中位观察期为46.5个月(范围10.0 - 120.0个月)。116例患者中共有18例复发,这些患者的中位复发时间为16.7个月(范围10.0 - 30.0个月)。接受大分割放疗(每次分割>2 Gy)和常规分割放疗(每次分割2 Gy)患者的控制率分别为88.5%和76.3%(P = 0.043)。计算生物学等效剂量(BED)>30 Gy和<30 Gy患者的控制率分别为89.7%和79.3%(P = 0.104)。根据不良事件通用术语标准v3.0,晚期无2级或更高等级的不良反应。未发现放疗与随后发生癌症之间存在关联的证据。本研究结果表明,大分割放疗作为瘢痕疙瘩手术切除后的辅助治疗发挥了重要作用。BED>30 Gy似乎足够。在随访期间未发现放疗与癌症发生之间存在明确关联的证据,然而,需要更多病例和更长的随访期。